Why the recent governance event at CVR Partners (UAN) matters for investors
CVR Partners (UAN) has disclosed the passing of independent director Brian A. Goebel, who chaired its Audit Committee, leaving the partnership temporarily out of compliance with New York Stock Exchange audit committee requirements.
The board now has five members, including two independent directors, and the Audit Committee has two independent members instead of the three required by NYSE rules. The partnership has informed the exchange and has started searching for a new independent director to restore compliance.
See our latest analysis for CVR Partners.
The governance setback comes alongside a sharp move in the unit price, with a 1-day share price return of 11.95% at US$128.73 and a 1-year total shareholder return of 92.86%. This suggests momentum has recently been strengthening rather than fading.
If this kind of governance driven volatility has your attention, it could be a good moment to broaden your search and look at 20 top founder-led companies as potential alternatives.
With units up 92.86% over the past year and an indicated intrinsic discount of about 33%, the key question now is whether CVR Partners is still trading at a discount or if the market is already pricing in future growth.
Price-to-Earnings of 13.8x: Is it justified?
On a P/E of 13.8x and a last close of $128.73, CVR Partners screens as cheaper than both its peer group on 30.3x and the wider US Chemicals industry on 25.8x. This points to a discount in how the market is pricing its earnings.
The P/E ratio compares the current unit price to earnings per unit. For a business producing nitrogen fertilizer and already profitable, it is a straightforward way to see what investors are paying for each dollar of earnings. When that multiple is well below peers, it often means the market is assigning a lower expectation to the durability or growth of those earnings, even when recent results have been strong.
Here, earnings growth of 62% over the past year, improving net profit margins from 11.6% to 16.3% and a shift to profitability over the past five years sit alongside that lower P/E. At the same time, the partnership carries a high level of debt and pays a dividend yield of 8.19% that is not well covered by earnings or free cash flow. Compared with the Chemicals industry average multiple of 25.8x, the 13.8x level is far lower. This is a strong contrast that suggests the market is valuing CVR Partners at a clear earnings discount relative to sector peers.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-Earnings of 13.8x (UNDERVALUED)
However, the high debt load and audit committee gap could still pressure sentiment if refinancing costs rise or if governance fixes take longer than investors expect.
Find out about the key risks to this CVR Partners narrative.
Another View: What Our DCF Model Suggests
While the 13.8x P/E points to an earnings discount, our DCF model tells a similar story. In that view, CVR Partners at $128.73 sits about 33% below an estimated future cash flow value of $193.65, which still presents it as undervalued. The question is whether you place more weight on current earnings or on long term cash flows.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CVR Partners for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If this mix of risks and rewards feels finely balanced, it may be worth considering taking action sooner rather than later and reviewing the details for yourself to see how 2 key rewards and 2 important warning signs lines up with your own view.
Looking for more investment ideas?
If CVR Partners has sharpened your focus, do not stop here. The Simply Wall St screener can quickly surface other opportunities that might better fit your style.
- Target steady compounding by scanning for companies with 50 high quality undervalued stocks that pair quality fundamentals with prices that currently sit below their estimated worth.
- Strengthen your income stream by focusing on reliable payers via 14 dividend fortresses, where payouts stand out for yield and resilience.
- Prioritise capital preservation by filtering for 67 resilient stocks with low risk scores that score well on financial strength and business stability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com